Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q1 EPS of ($0.14), $0.20 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Wolfe Research sees CNH stock flat 2027 outlook on commodity prices
• Jefferies sees metals breakout on currency concerns